Median estimates from the three datasets analyzed suggest at least half of all Ebola virus disease spillover events (possibly as many as 83 percent) have gone undetected.
Researchers developed a new methodology that monitors the number of survivors (adaptive capacity) rather than focusing on the confirmed number of cases (impact).
High levels of neutralizing antibodies didn’t appear in patients’ blood until months after patients left the hospital. This information could be used to establish a benchmark of immune protection after vaccination.
Researchers generated two antibodies to the Ebola virus, which potentially could be used in a simple filter paper test to detect the Ebola and Marburg viruses.
Japan's health ministry and the National Institute of Infectious Diseases are considering importing frozen pathogens of Ebola, Crimean-Congo fever, Marburg, and Lassa fever.
The microfluidic device that utilizes gene-editing technology to monitor and detect the nucleic acid markers that indicate Ebola virus, allowing for earlier detection and presumably treatment of Ebola virus disease.
The exercise involved hospitals, paramedics, and county health departments.
This video presents a case study about caring for patients with Ebola virus disease at Nebraska Medical Center in 2014.
The University of Texas Medical Branch at Galveston, Profectus Biosciences, Vanderbilt University Medical Center, Mapp Biopharmaceutical and Genevant Sciences Corp. have been awarded up to $35 million to advance the development of rapid-acting vaccines and broad-spectrum treatments of the highly-lethal hemorrhagic fever viruses Ebola and Marburg.
Intradermal administration of a DNA Ebola vaccine candidate using electroporation showed improvements over intramuscular administration in a recent study that found the new approach to Ebola prevention to be well-tolerated and effective.